Healthcare | August 13, 2021
HCG Q1 revenue at Rs 326.58 cr. 67 per cent increase YoY
Substantial reduction in losses
Substantial reduction in losses
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
The transaction is expected to close in the Q4FY22
Aditya Puri former MD of HDFC bank joins Solara board as chairman
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
The company posted net profit of Rs.594.6 crores for the period ended June 30, 2020.
Subscribe To Our Newsletter & Stay Updated
